Bank of New York Mellon Corp Has $896,000 Stock Position in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Bank of New York Mellon Corp raised its position in GoodRx Holdings, Inc. (NASDAQ:GDRX) by 10.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 192,612 shares of the company’s stock after purchasing an additional 17,633 shares during the quarter. Bank of New York Mellon Corp’s holdings in GoodRx were worth $896,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. EP Wealth Advisors LLC acquired a new stake in shares of GoodRx in the 3rd quarter valued at $73,000. Sanctuary Advisors LLC bought a new position in GoodRx during the third quarter valued at about $85,000. Quest Partners LLC bought a new position in GoodRx during the third quarter valued at about $160,000. JPMorgan Chase & Co. lifted its position in shares of GoodRx by 358.7% in the third quarter. JPMorgan Chase & Co. now owns 24,293 shares of the company’s stock worth $169,000 after buying an additional 18,997 shares during the last quarter. Finally, Sugar Maple Asset Management LLC bought a new stake in shares of GoodRx during the 4th quarter worth about $122,000. 63.77% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have commented on GDRX shares. Citigroup lowered their price target on GoodRx from $7.00 to $6.25 and set a “buy” rating on the stock in a report on Friday, January 10th. Morgan Stanley dropped their price objective on GoodRx from $7.00 to $6.00 and set an “equal weight” rating on the stock in a research note on Tuesday, December 17th. Mizuho started coverage on GoodRx in a research note on Wednesday, December 4th. They set a “neutral” rating and a $5.00 target price for the company. KeyCorp dropped their price target on GoodRx from $7.00 to $6.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th. Finally, Wells Fargo & Company reduced their price objective on GoodRx from $9.00 to $8.00 and set an “overweight” rating for the company in a research report on Friday, February 28th. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $8.18.

GoodRx Stock Performance

Shares of GDRX stock opened at $4.55 on Wednesday. GoodRx Holdings, Inc. has a 12 month low of $4.09 and a 12 month high of $9.26. The company’s fifty day simple moving average is $4.76 and its 200-day simple moving average is $5.35. The firm has a market cap of $1.75 billion, a PE ratio of -151.67, a P/E/G ratio of 2.46 and a beta of 1.25. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.